ArticleFrontiers in public health2026
Myasthenia gravis in Latin America and the Caribbean: epidemiology, resources, and accessibility to diagnosis and treatment.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Latin-American and Caribbean (LAC) countries face persistent challenges in achieving universal health coverage, with out-of-pocket healthcare expenditures posing a significant barrier. Access to care for rare diseases, such as myasthenia gravis (MG), is significantly impacted. We conducted an exploratory descriptive study between LAC countries, and we assessed the availability of diagnostic and therapeutic resources for MG across 12 LAC countries, along with associated costs and access barriers. We found marked inequalities regarding the availability and coverage of diagnostic tests and therapies by public healthcare systems. The elevated out-of-pocket costs, up to several times the minimum wage, and shortage of neurologists, makes appropriate diagnosis and treatments inaccessible for many patients living with MG. Novel treatments for MG are unavailable for most people with MG in Latin America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.